| MeSH term | MeSH ID | Detail |
|---|---|---|
| Breast Neoplasms | D001943 | 24 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Melanoma | D008545 | 69 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
| Hyperplasia | D006965 | 34 associated lipids |
| Leukemia | D007938 | 74 associated lipids |
| Leukemia, Myeloid | D007951 | 52 associated lipids |
| Bronchial Spasm | D001986 | 18 associated lipids |
| Lymphoma, B-Cell | D016393 | 24 associated lipids |
| Asthenia | D001247 | 5 associated lipids |
| Hypopharyngeal Neoplasms | D007012 | 1 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| pmid: | ||||
| Khot A et al. | Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1. | 2017 | AAPS J | pmid:28808917 |
| Bender B et al. | A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer. | 2014 | AAPS J | pmid:24917179 |
| Ait-Oudhia S et al. | A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates. | 2017 | AAPS J | pmid:28646408 |
| Loebrich S et al. | Development and Characterization of a Neutralizing Anti-idiotype Antibody Against Mirvetuximab for Analysis of Clinical Samples. | 2017 | AAPS J | pmid:28534292 |
| Singh AP and Shah DK | Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1). | 2017 | AAPS J | pmid:28374319 |
| Erickson HK and Lambert JM | ADME of antibody-maytansinoid conjugates. | 2012 | AAPS J | pmid:22875610 |
| Cilliers C et al. | Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy. | 2016 | AAPS J | pmid:27287046 |
| Singh AP et al. | Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1). | 2016 | AAPS J | pmid:27029797 |
| Maass KF et al. | Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design. | 2016 | AAPS J | pmid:26912181 |
| Chari RV | Targeted cancer therapy: conferring specificity to cytotoxic drugs. | 2008 | Acc. Chem. Res. | pmid:17705444 |
| Kim SU et al. | Neurofibrillary degeneration in cultured adult mouse neurons induced by maytansine. | 1980 | Acta Neuropathol. | pmid:7435167 |
| Kolarich AR et al. | Ado-trastuzamab emtansine associated hyponatremia and intracranial hemorrhage. | 2014 | Acta Oncol | pmid:24834794 |
| Dymowski W and Furmanowa M | [Investigating cytostatic substances in tissue of plants Maytenus Molina in in-vitro cultures. II. chromatographic test of extracts from callus of Maytenus wallichiana R. et B]. | 1990 | Acta Pol Pharm | pmid:1669332 |
| Lambert JM and Morris CQ | Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review. | 2017 | Adv Ther | pmid:28361465 |
| Friedkin M and Rozengurt E | The role of cytoplasmic microtubules in the regulation of the activity of peptide growth factors. | 1980 | Adv. Enzyme Regul. | pmid:7039258 |
| Patel KC et al. | Ado-trastuzumab emtansine for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer. | 2014 | Am J Health Syst Pharm | pmid:24644113 |
| Traynor K | Ado-trastuzumab emtansine approved for advanced breast cancer. | 2013 | Am J Health Syst Pharm | pmid:23515502 |
| Muzaffar M et al. | Acute Pancreatitis Associated With Ado-Trastuzumab Emtansine. | Am J Ther | pmid:25756468 | |
| Esteva FJ et al. | What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience? | 2015 | Am Soc Clin Oncol Educ Book | pmid:25993162 |
| Stinchcombe TE | Novel formulations and new mechanisms of delivering chemotherapy. | 2014 | Am Soc Clin Oncol Educ Book | pmid:24857128 |
| Martin M and López-Tarruella S | Emerging Therapeutic Options for HER2-Positive Breast Cancer. | 2016 | Am Soc Clin Oncol Educ Book | pmid:27249772 |
| Thigpen JT et al. | Phase II study of maytansine in the treatment of advanced or recurrent adenocarcinoma of the ovary. A Gynecologic Oncology Group study. | 1983 | Am. J. Clin. Oncol. | pmid:6846245 |
| Thigpen JT et al. | Phase II study of maytansine in the treatment of advanced or recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study. | 1983 | Am. J. Clin. Oncol. | pmid:6869315 |
| Borden EC et al. | Phase II evaluation of dibromodulcitol, ICRF-159, and maytansine for sarcomas. | 1982 | Am. J. Clin. Oncol. | pmid:6956236 |
| Slavik M et al. | Phase II studies in advanced, recurrent pelvic malignancies: conducted by the Gynecologic Oncology Group, Experimental Design and Experience. | 1982 | Am. J. Clin. Oncol. | pmid:6897490 |
| Ravry MJ et al. | Phase II evaluation of maytansine (NSC 153858) in advanced cancer. A Southeastern Cancer Study Group trial. | 1985 | Am. J. Clin. Oncol. | pmid:3834790 |
| Fleming MS et al. | A reversed-phase high-performance liquid chromatography method for analysis of monoclonal antibody-maytansinoid immunoconjugates. | 2005 | Anal. Biochem. | pmid:15840500 |
| Luo Q et al. | Structural Characterization of a Monoclonal Antibody-Maytansinoid Immunoconjugate. | 2016 | Anal. Chem. | pmid:26629796 |
| Sang H et al. | Conjugation site analysis of antibody-drug-conjugates (ADCs) by signature ion fingerprinting and normalized area quantitation approach using nano-liquid chromatography coupled to high resolution mass spectrometry. | 2017 | Anal. Chim. Acta | pmid:28088282 |
| Eichner S et al. | The interplay between mutasynthesis and semisynthesis: generation and evaluation of an ansamitocin library. | 2012 | Angew. Chem. Int. Ed. Engl. | pmid:22135226 |
| Monneret C | [Current impact of natural products in the discovery of anticancer drugs]. | 2010 | Ann Pharm Fr | pmid:20637355 |
| Corrigan PA et al. | Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate. | 2014 | Ann Pharmacother | pmid:25082874 |
| Leal M et al. | Antibody-drug conjugates: an emerging modality for the treatment of cancer. | 2014 | Ann. N. Y. Acad. Sci. | pmid:25123209 |
| Luduena RF et al. | Interactions of vinblastine and maytansine with tubulin. | 1986 | Ann. N. Y. Acad. Sci. | pmid:3460446 |
| Krop IE et al. | Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. | 2015 | Ann. Oncol. | pmid:25355722 |
| Martin M et al. | Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. | 2016 | Ann. Oncol. | pmid:27052654 |
| Gebhart G et al. | Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. | 2016 | Ann. Oncol. | pmid:26598545 |
| Foglietta J et al. | Letter to the editor concerning 'Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA'. | 2015 | Ann. Oncol. | pmid:25632067 |
| Olson EM et al. | Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. | 2012 | Ann. Oncol. | pmid:21531783 |
| Sibaud V et al. | T-DM1-related telangiectasias: a potential role in secondary bleeding events. | 2015 | Ann. Oncol. | pmid:25403586 |
| Gradishar WJ | Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab. | 2013 | Ann. Oncol. | pmid:23827380 |
| Wall ME and Wani MC | Antineoplastic agents from plants. | 1977 | Annu. Rev. Pharmacol. Toxicol. | pmid:326159 |
| Maslin DN | [Ansamycins]. | 1979 | Antibiotiki | pmid:37801 |
| Mescher C et al. | Left Ventricular Ejection Fraction Screening and Clinical Decision-making in Metastatic HER2-positive Breast Cancer. | 2017 | Anticancer Res. | pmid:28668870 |
| Michel LL et al. | T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice. | 2015 | Anticancer Res. | pmid:26254411 |
| Tanida S et al. | Inhibition of cilia regeneration of Tetrahymena by ansamitocins, new antitumor antibiotics. | 1979 | Antimicrob. Agents Chemother. | pmid:475367 |
| Hanka LJ and Barnett MS | Microbiological assays and bioautography of maytansine and its homologues. | 1974 | Antimicrob. Agents Chemother. | pmid:15825322 |
| Zhao M et al. | Effects of the Methylmalonyl-CoA Metabolic Pathway on Ansamitocin Production in Actinosynnema pretiosum. | 2017 | Appl. Biochem. Biotechnol. | pmid:27787765 |
| Li T et al. | Improvement of ansamitocin P-3 production by Actinosynnema mirum with fructose as the sole carbon source. | 2015 | Appl. Biochem. Biotechnol. | pmid:25564203 |
| Fan Y et al. | Enhancement of UDPG synthetic pathway improves ansamitocin production in Actinosynnem pretiosum. | 2016 | Appl. Microbiol. Biotechnol. | pmid:26585444 |
| Li S et al. | Constitutive overexpression of asm18 increases the production and diversity of maytansinoids in Actinosynnema pretiosum. | 2016 | Appl. Microbiol. Biotechnol. | pmid:26572523 |
| Luduena RF and Roach MC | Contrasting effects of maytansine and vinblastine on the alkylation of tubulin sulfhydryls. | 1981 | Arch. Biochem. Biophys. | pmid:7305339 |
| Ludueña RF et al. | The interaction of phomopsin A with bovine brain tubulin. | 1989 | Arch. Biochem. Biophys. | pmid:2735765 |
| Ma J et al. | New amide N-glycosides of ansamitocins identified from Actinosynnema pretiosum. | 2007 | Arch. Pharm. Res. | pmid:17679541 |
| Jin W et al. | LC-HRMS quantitation of intact antibody drug conjugate trastuzumab emtansine from rat plasma. | 2018 | Bioanalysis | pmid:29863890 |
| Carrasco-Triguero M et al. | Immunogenicity assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine. | 2013 | Bioanalysis | pmid:23641693 |
| Dere R et al. | PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine. | 2013 | Bioanalysis | pmid:23641694 |
| Mandelbaum-Shavit F et al. | Binding of maytansine to rat brain tubulin. | 1976 | Biochem. Biophys. Res. Commun. | pmid:985482 |
| Morimura O et al. | Trastuzumab emtansine suppresses the growth of HER2-positive small-cell lung cancer in preclinical models. | 2017 | Biochem. Biophys. Res. Commun. | pmid:28526406 |
| Li Y et al. | Binding selectivity of rhizoxin, phomopsin A, vinblastine, and ansamitocin P-3 to fungal tubulins: differential interactions of these antimitotic agents with brain and fungal tubulins. | 1992 | Biochem. Biophys. Res. Commun. | pmid:1530630 |
| Banerjee A et al. | Interaction of reduced glutathione with bovine brain tubulin. | 1985 | Biochem. Biophys. Res. Commun. | pmid:3994709 |
| Huang AB et al. | Maytansine inhibits nucleotide binding at the exchangeable site of tubulin. | 1985 | Biochem. Biophys. Res. Commun. | pmid:4004859 |
| Johnson RK et al. | Stathmokinetic and therapeutic effects of maytansine in mice bearing P388 and L1210 leukemias. | 1978 | Biochem. Pharmacol. | pmid:708479 |
| York J et al. | Binding of maytansinoids to tubulin. | 1981 | Biochem. Pharmacol. | pmid:7317106 |
| Ikeyama S and Takeuchi M | Antitubulin activities of ansamitocins and maytansinoids. | 1981 | Biochem. Pharmacol. | pmid:21043240 |
| Ludueña RF et al. | Effect of phomopsin A on the alkylation of tubulin. | 1990 | Biochem. Pharmacol. | pmid:2337418 |
| Li Y et al. | Interaction of phomopsin A with porcine brain tubulin. Inhibition of tubulin polymerization and binding at a rhizoxin binding site. | 1992 | Biochem. Pharmacol. | pmid:1739410 |
| Lacey E et al. | Interaction of phomopsin A and related compounds with purified sheep brain tubulin. | 1987 | Biochem. Pharmacol. | pmid:3606630 |
| Duanmu C et al. | Tubulin polymerization with ATP is mediated through the exchangeable GTP site. | 1986 | Biochim. Biophys. Acta | pmid:3004597 |
| Takahashi M et al. | Rhizoxin binding to tubulin at the maytansine-binding site. | 1987 | Biochim. Biophys. Acta | pmid:3120782 |
| van Geel R et al. | Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody-Drug Conjugates. | 2015 | Bioconjug. Chem. | pmid:26061183 |
| Ito K et al. | Near-Infrared Photochemoimmunotherapy by Photoactivatable Bifunctional Antibody-Drug Conjugates Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancer. | 2017 | Bioconjug. Chem. | pmid:28402624 |
| Sun X et al. | Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates. | 2017 | Bioconjug. Chem. | pmid:28388844 |
| Sawada T et al. | A fluorescent probe and a photoaffinity labeling reagent to study the binding site of maytansine and rhizoxin on tubulin. | 1993 Jul-Aug | Bioconjug. Chem. | pmid:8218485 |
| Chen Y et al. | Structural Characterization of Cross-Linked Species in Trastuzumab Emtansine (Kadcyla). | 2016 | Bioconjug. Chem. | pmid:27458087 |
| Ponte JF et al. | Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates. | 2016 | Bioconjug. Chem. | pmid:27174129 |
| Widdison WC et al. | Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolites in Cancer Cells and Induce High Levels of Bystander Killing. | 2015 | Bioconjug. Chem. | pmid:26355774 |
| Wakankar AA et al. | Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes. | 2010 | Bioconjug. Chem. | pmid:20698491 |
| Sun X et al. | Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism. | 2011 | Bioconjug. Chem. | pmid:21391620 |
| Kellogg BA et al. | Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. | 2011 | Bioconjug. Chem. | pmid:21425776 |
| Kim MT et al. | Statistical modeling of the drug load distribution on trastuzumab emtansine (Kadcyla), a lysine-linked antibody drug conjugate. | 2014 | Bioconjug. Chem. | pmid:24873191 |
| Erickson HK et al. | Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. | 2010 | Bioconjug. Chem. | pmid:19891424 |
| Stephan JP et al. | Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. | 2008 | Bioconjug. Chem. | pmid:18637680 |
| Nakao H et al. | Cytotoxic activity of maytanprine isolated from Maytenus diversifolia in human leukemia K562 cells. | 2004 | Biol. Pharm. Bull. | pmid:15305028 |
| Zhong P et al. | Glutathione-Sensitive Hyaluronic Acid-SS-Mertansine Prodrug with a High Drug Content: Facile Synthesis and Targeted Breast Tumor Therapy. | 2016 | Biomacromolecules | pmid:27723970 |
| Bellat V et al. | Smart Nanotransformers with Unique Enzyme-Inducible Structural Changes and Drug Release Properties. | 2016 | Biomacromolecules | pmid:27180972 |
| Arai MA et al. | Hedgehog/GLI-mediated transcriptional inhibitors from Zizyphus cambodiana. | 2008 | Bioorg. Med. Chem. | pmid:18842418 |
| Nittoli T et al. | Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids. | 2018 | Bioorg. Med. Chem. | pmid:29605304 |
| Lin J and Zhong JJ | Proteomic studies on anti-tumor agent ansamitocin P-3 producer Actinosynnema pretiosum in response to ammonium and isobutanol. | 2017 | Bioprocess Biosyst Eng | pmid:28382459 |
| Lin J et al. | Enhanced production of ansamitocin P-3 by addition of isobutanol in fermentation of Actinosynnema pretiosum. | 2011 | Bioresour. Technol. | pmid:20980145 |
| Jia Y and Zhong JJ | Enhanced production of ansamitocin P-3 by addition of Mg2+ in fermentation of Actinosynnema pretiosum. | 2011 | Bioresour. Technol. | pmid:21907573 |
| Ning X et al. | Identification and Engineering of Post-PKS Modification Bottlenecks for Ansamitocin P-3 Titer Improvement in Actinosynnema pretiosum subsp. pretiosum ATCC 31280. | 2017 | Biotechnol J | pmid:28881098 |
| Du ZQ et al. | Combination of traditional mutation and metabolic engineering to enhance ansamitocin P-3 production in Actinosynnema pretiosum. | 2017 | Biotechnol. Bioeng. | pmid:28782796 |
| Oki T | Cytotoxic and antitumor antibiotics produced by microorganisms. | 1980 | Biotechnol. Bioeng. | pmid:6159010 |
| Tassone P et al. | Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. | 2004 | Blood | pmid:15292058 |
| Matsubara Y | A Meg by any other name. | 2012 | Blood | pmid:22956528 |
| Thon JN et al. | High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)--mediated inhibition of platelet production. | 2012 | Blood | pmid:22665936 |
| Deckert J et al. | A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. | 2013 | Blood | pmid:24002446 |
| Palomba ML and Younes A | In the spotlight: a novel CD37 antibody-drug conjugate. | 2013 | Blood | pmid:24235129 |